RxDoctor Payments Data

Carl Gerardi, MD

Urology · Yonkers, NYNPI 1730104936

Payments from drug & device makers

$20,382in general payments, 2019–2025

Across 677 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$2K
  • Boston Scientific$2K
  • Johnson & Johnson$2K
  • Teleflex LLC$1K
  • Urogen Pharma, Inc.$1K
  • Sumitomo Pharma America, Inc.$1K
  • plus $10K from 44 others

What the payments were for

  • Food & beverage$19,48396%
  • Education$8994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,382 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$513,085
Medicare patients
470
Services billed
15,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide33$464,145
ErleadaApalutamide17$239,823
MyrbetriqMirabegron88$67,892
GemtesaVibegron57$56,077
OrgovyxRelugolix15$40,837
Mirabegron ErMirabegron13$6,048
FirmagonDegarelix Acetate12$5,487
Testosterone Cypionate60$4,534
Silodosin26$2,885
Tadalafil18$2,486
Solifenacin Succinate22$1,824
Tamsulosin Hcl134$1,468
CefuroximeCefuroxime Axetil124$1,338
Alfuzosin Hcl ErAlfuzosin Hcl45$908
Finasteride44$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$2,084$532,036121 claims
Johnson & JohnsonErleada$2,000$239,82317 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,329$96,91472 claims
Ferring Pharmaceuticals Inc.Firmagon$293$5,48712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →